These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6454542)

  • 1. Clinical efficacy of moxalactam with emphasis on infections due to multidrug-resistant organisms in patients with renal insufficiency.
    Trager GM; Panwalker AP; Malow JB; Porembski PE; Ramirez CA; Zar FA
    Chemotherapy; 1981; 27(4):287-95. PubMed ID: 6454542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxalactam therapy for bacterial infections.
    Winston DJ; Busuttil RW; Kurtz TO; Young LS
    Arch Intern Med; 1981 Nov; 141(12):1607-12. PubMed ID: 6458253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxalactam in serious infections: clinical, bacteriologic, and pharmacokinetic studies.
    Giamarellou H; Tsagarakis J; Daikos GK
    Rev Infect Dis; 1982; 4 Suppl():S629-38. PubMed ID: 6218576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.
    Platt R; Ehrlich SL; Afarian J; O'Brien TF; Pennington JE; Kass EH
    Antimicrob Agents Chemother; 1981 Sep; 20(3):351-5. PubMed ID: 6458233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of serious infections with moxalactam.
    Ribner BS; Raeder R; Becker TM; Freimer EH
    Am J Med; 1983 Mar; 74(3):396-400. PubMed ID: 6219576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxalactam therapy for a wide spectrum of bacterial infections in adults.
    Tofte RW; Rotschafer J; Solliday J; Crossley KB
    Antimicrob Agents Chemother; 1981 May; 19(5):740-4. PubMed ID: 6457555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of moxalactam: evidence of decreased efficacy in gram-positive aerobic infections.
    Salzer W; Pegram PS; McCall CE
    Antimicrob Agents Chemother; 1983 Apr; 23(4):565-70. PubMed ID: 6222696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxalactam: clinical summary of efficacy and safety.
    Kammer RB
    Rev Infect Dis; 1982; 4 Suppl():S712-9. PubMed ID: 6218589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxalactam therapy vs. standard antimicrobial therapy for selected serious infections.
    Oblinger MJ; Bowers JT; Sande MA; Mandell GL
    Rev Infect Dis; 1982; 4 Suppl():S639-49. PubMed ID: 6218577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of moxalactam.
    Mathisen GE; Meyer RD; Thompson JM; Finegold SM
    Antimicrob Agents Chemother; 1982 May; 21(5):780-6. PubMed ID: 6213198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli.
    Fisher JF; Carter MJ; Parsons J; Rissing JP
    Antimicrob Agents Chemother; 1981 Feb; 19(2):218-21. PubMed ID: 6214985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drug evaluations: moxalactam (Moxam, Eli Lilly).
    Polk RE
    Drug Intell Clin Pharm; 1982 Feb; 16(2):104-12. PubMed ID: 6210519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and clinical efficacy of moxalactam in biliary tract infections.
    Mueller O; Fabricius K; Krueger E; Rueckert U
    Rev Infect Dis; 1982; 4 Suppl():S688-91. PubMed ID: 6218584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of 18 cases of purulent meningitis with moxalactam. Pharmacokinetic data].
    Modai J; Vittecoq D; Decazes JM; Wolff M; Meulemans A
    Presse Med; 1983 Jan; 12(3):139-42. PubMed ID: 6220351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pharmacokinetic evaluation of moxalactam in infants and children.
    Varghese M; Khan AJ; Quaye G; Patel U; Kumar K; Evans HE
    Chemotherapy; 1982; 28(6):417-20. PubMed ID: 6218971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.
    Preheim LC; Penn RG; Sanders CC; Goering RV; Giger DK
    Antimicrob Agents Chemother; 1982 Dec; 22(6):1037-41. PubMed ID: 6218778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxalactam therapy of bacterial meningitis in adults.
    Uwaydah M; Tannir N; Kantarjian H; Osseiran M; Bal'a F
    Antimicrob Agents Chemother; 1983 Feb; 23(2):289-92. PubMed ID: 6220673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Moxalactam - a beta-lactam antibiotic in the monotherapy of severe infections in surgery. Clinico-bacteriological study of 35 patients].
    Gonzenbach HR; Sonnabend W
    Schweiz Med Wochenschr; 1981 Aug; 111(31-32):1169-83. PubMed ID: 6456543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Moxalactam in pediatrics. Clinical and pharmacokinetic experience. Apropos of 37 cases].
    Bégué P; Safran C; Fleurette J; Brun Y; Floret D; Monnet P
    Sem Hop; 1983 Jun; 59(26):1972-6. PubMed ID: 6310789
    [No Abstract]   [Full Text] [Related]  

  • 20. [Susceptibility of recent clinical isolates of Pseudomonas aeruginosa and Serratia marcescens to cefotaxime, ceftizoxime, cefmenoxime, latamoxef and cefsulodin in comparison with other beta-lactam antibiotics and aminoglycosides].
    Kawakami Y; Okimura Y; Horiuchi N; Kanai M
    Jpn J Antibiot; 1982 Sep; 35(9):2314-7. PubMed ID: 6292543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.